Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 06 - 11 save search
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19
Published: 2021-06-11 (Crawled : 13:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.92%
H: 2.83%
C: -5.66%
covid treatment phase 2 phase 2/3 trial
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -3.27%
H: 0.39%
C: -2.47%
new drug treatment fda dermatitis drug atopic dermatitis application
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
EQ | $1.63 -5.78% -6.13% 100K
|
Health Technology
|
| O: -6.16%
H: 0.31%
C: -6.41%
disease treatment positive results topline
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
Published: 2021-06-11 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.92%
H: 2.83%
C: -5.66%
covid treatment trial
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -10.49%
H: 3.1%
C: -0.53%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 4.42%
H: 0.63%
C: -1.69%
crispr treatment europe therapy ctx001
Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
EDIT | $5.5 -0.9% -0.91% 2.3M
|
Health Technology
|
| O: 1.73%
H: 1.89%
C: -0.32%
disease treatment europe phase 1 trial phase 3 preclinical pre-clinical
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Published: 2021-06-11 (Crawled : 08:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.86%
H: 0.91%
C: 0.0%
treatment gene therapy therapy license gene therapies syndros
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: -0.61%
treatment blood therapy rare
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.13%
H: 0.11%
C: -0.09%
treatment potential anemia
Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH
Published: 2021-06-11 (Crawled : 06:00) - prnewswire.com
PTCT | News S | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: -0.23%
H: 0.77%
C: -0.28%
treatment children milestone muscular atrophy
New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
Published: 2021-06-11 (Crawled : 06:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.0%
H: 0.1%
C: -0.71%
treatment leukemia
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.